These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 20737636)

  • 1. Enhancement of the aqueous solubility and masking the bitter taste of famotidine using drug/SBE-beta-CyD/povidone K30 complexation approach.
    Mady FM; Abou-Taleb AE; Khaled KA; Yamasaki K; Iohara D; Ishiguro T; Hirayama F; Uekama K; Otagiri M
    J Pharm Sci; 2010 Oct; 99(10):4285-94. PubMed ID: 20737636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of carboxymethyl-beta-cyclodextrin with acid function: improvement of chemical stability, oral bioavailability and bitter taste of famotidine.
    Mady FM; Abou-Taleb AE; Khaled KA; Yamasaki K; Iohara D; Taguchi K; Anraku M; Hirayama F; Uekama K; Otagiri M
    Int J Pharm; 2010 Sep; 397(1-2):1-8. PubMed ID: 20600734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation and evaluation of taste masked famotidine formulation using drug/beta-cyclodextrin/polymer ternary complexation approach.
    Patel AR; Vavia PR
    AAPS PharmSciTech; 2008; 9(2):544-50. PubMed ID: 18431648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulation and biological evaluation of glimepiride-cyclodextrin-polymer systems.
    Ammar HO; Salama HA; Ghorab M; Mahmoud AA
    Int J Pharm; 2006 Feb; 309(1-2):129-38. PubMed ID: 16377107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Slow-release of famotidine from tablets consisting of chitosan/sulfobutyl ether β-cyclodextrin composites.
    Anraku M; Hiraga A; Iohara D; Pipkin JD; Uekama K; Hirayama F
    Int J Pharm; 2015 Jun; 487(1-2):142-7. PubMed ID: 25882010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of some physicochemical properties of arundic acid, (R)-(-)-2-propyloctanonic acid, by complexation with hydrophilic cyclodextrins.
    Miyamoto Y; Nakahara M; Motoyama K; Ishiguro T; Oda Y; Yamanoi T; Okamoto I; Yagi A; Nishimura H; Hirayama F; Uekama K; Arima H
    Int J Pharm; 2011 Jul; 413(1-2):63-72. PubMed ID: 21540089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stabilizing and solubilizing effects of sulfobutyl ether beta-cyclodextrin on prostaglandin E1 analogue.
    Uekama K; Hieda Y; Hirayama F; Arima H; Sudoh M; Yagi A; Terashima H
    Pharm Res; 2001 Nov; 18(11):1578-85. PubMed ID: 11758766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implication of inclusion complexation of glimepiride in cyclodextrin-polymer systems on its dissolution, stability and therapeutic efficacy.
    Ammar HO; Salama HA; Ghorab M; Mahmoud AA
    Int J Pharm; 2006 Aug; 320(1-2):53-7. PubMed ID: 16701974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of preparation methodology on solid-state properties of an acidic drug-cyclodextrin system.
    Govindarajan R; Nagarsenker MS
    J Pharm Pharmacol; 2004 Jun; 56(6):725-33. PubMed ID: 15231037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The formation of an inclusion complex between a metabolite of ginsenoside, compound K and γ-cyclodextrin and its dissolution characteristics.
    Igami K; Ozawa M; Inoue S; Iohara D; Miyazaki T; Shinoda M; Anraku M; Hirayama F; Uekama K
    J Pharm Pharmacol; 2016 May; 68(5):646-54. PubMed ID: 26255976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced solubility and dissolution rate of lamotrigine by inclusion complexation and solid dispersion technique.
    Shinde VR; Shelake MR; Shetty SS; Chavan-Patil AB; Pore YV; Late SG
    J Pharm Pharmacol; 2008 Sep; 60(9):1121-9. PubMed ID: 18718114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experimental, molecular docking investigations and bioavailability study on the inclusion complexes of finasteride and cyclodextrins.
    Mady FM; Farghaly Aly U
    Drug Des Devel Ther; 2017; 11():1681-1692. PubMed ID: 28652706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing the solubility and masking the bitter taste of propiverine using crystalline complex formation.
    Ogata T; Tanaka D; Ozeki T
    Drug Dev Ind Pharm; 2014 Aug; 40(8):1084-91. PubMed ID: 23789589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Taste masking microspheres for orally disintegrating tablets.
    Xu J; Bovet LL; Zhao K
    Int J Pharm; 2008 Jul; 359(1-2):63-9. PubMed ID: 18455893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of some pharmaceutical properties of DY-9760e by sulfobutyl ether beta-cyclodextrin.
    Nagase Y; Hirata M; Wada K; Arima H; Hirayama F; Irie T; Kikuchi M; Uekama K
    Int J Pharm; 2001 Oct; 229(1-2):163-72. PubMed ID: 11604269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of Pharmaceutical Properties of Zerumbone, a Multifunctional Compound, Using Cyclodextrin Derivatives.
    Hassan MM; Mohammed AFA; Elamin KM; Devkota HP; Ohno Y; Motoyama K; Higashi T; Imai T
    Chem Pharm Bull (Tokyo); 2020; 68(11):1117-1120. PubMed ID: 33132380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats.
    Arima H; Yunomae K; Miyake K; Irie T; Hirayama F; Uekama K
    J Pharm Sci; 2001 Jun; 90(6):690-701. PubMed ID: 11357172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binary and ternary inclusion complexes of finasteride in HPbetaCD and polymers: preparation and characterization.
    Asbahr AC; Franco L; Barison A; Silva CW; Ferraz HG; Rodrigues LN
    Bioorg Med Chem; 2009 Apr; 17(7):2718-23. PubMed ID: 19282187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of dissolution properties of a new Helicobacter pylori eradicating agent (TG44) by inclusion complexation with beta-cyclodextrin.
    Anzai K; Mizoguchi J; Yanagi T; Hirayama F; Arima H; Uekama K
    Chem Pharm Bull (Tokyo); 2007 Oct; 55(10):1466-70. PubMed ID: 17917290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of cyclodextrins on the solubility and stability of candesartan cilexetil in solution and solid state.
    Al Omari AA; Al Omari MM; Badwan AA; Al-Sou'od KA
    J Pharm Biomed Anal; 2011 Feb; 54(3):503-9. PubMed ID: 20971593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.